Biogen Idec Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2012. For the quarter, the company reported net income attributable to the company of $292,127,000 or $1.23 per basic and diluted share on total revenues of $1,417,941,000 compared to net income attributable to the company of $300,238,000 or $1.22 per diluted share on total revenues of $1,326,710,000 a year ago. Income from operations was $445,507,000 compared to $409,103,000 a year ago. Income before income tax expense and equity in loss of investee, net of tax was $431,217,000 compared to $405,130,000 a year ago. Net income was $292,127,000 compared to $300,211,000 a year ago. Non-GAAP net income attributable to the company was $334,600,000 or $1.40 per diluted share compared to $370,200,000 or $1.51 per diluted share a year ago.

For the year, the company reported net income attributable to the company of $1,380,033,000 or $5.76 per diluted share on total revenues of $5,516,461,000 compared to net income attributable to the company of $1,234,428,000 or $5.04 per diluted share on total revenues of $5,048,634,000 a year ago. Income from operations was $1,855,849,000 compared to $1,724,691,000 a year ago. Income before income tax expense and equity in loss of investee, net of tax was $1,855,105,000 compared to $1,711,214,000 a year ago. Net income was $1,380,033,000 compared to $1,266,686,000 a year ago. Non-GAAP net income attributable to the company was $1,566,600,000 or $6.53 per diluted share compared to $1,446,200,000 or $5.90 per diluted share a year ago.

The company provided earnings guidance for the full year 2013. For the period, the company's revenue growth is expected to be approximately 10%. Tax expense is expected to be approximately 24% to 26% of pretax income. Non-GAAP diluted EPS is expected to be between $7.15 and $7.25. GAAP diluted EPS is expected to be between $6.45 and $6.55. capital expenditures are expected to be in the range of $250 million to $270 million.